Research

Longevity Science: Research Claims, Commercial Incentives, and Human Lifespan Extension

Longevity science investment more than doubled to $8.49 billion in 2024, but the field's central tension is that no candidate intervention — rapamycin, NMN, senolytics, or metformin — yet has completed large-scale human outcomes trials, leaving a significant gap between commercial momentum and clinical proof. The field is simultaneously fractured by foundational disagreements: whether aging should be classified as a disease (contested by regulators in Japan, Saudi Arabia, and the FDA itself), whether interventions will compress late-life illness or extend decline, and whether the industry's data practices constitute, as Indian geriatricians argue, a form of biopiracy that extracts knowledge from Global South populations while pricing solutions beyond their reach. A busy reader should know that the science is structurally promising but evidentially immature, and that the equity and regulatory questions are not peripheral concerns — they are actively shaping what research gets funded, what gets approved, and who benefits.